glp-1 receptor agonist use and risk of suicide death therapy may reduce suicidal ideation for adolescents with obesity GLP-1 Receptor Agonists for the

Longterm use of GLP1 receptor agonists is generally welltolerated, but clinicians should monitor for gastrointestinal side effects, rare risks like pancreatitis, and individual response

Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ

Research Evidence Comparison# Retatrutide Research# Phase 1 : First-in-human study established safety and pharmacokinetics Phase 2 (n=338) : Published in NEJM (2023), demonstrated dose-dependent weight loss up to 24.2% at 48 weeks with 12 mg dose

Treatment usually starts at a low dose to minimise nausea, then increases gradually over several weeks

Keep lyophilized powder protected from light and moisture

Authorship All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published